Sanofi India declares 12 percent growth in operating profits despite NLEM impact in Q2
Mumbai: Sanofi India Limited (SIL) has declared its financial results for the quarter and half year ended on June 30th, 2023. The Company has delivered revenue growth of 2% for the quarter ended 30th June 2023 on a comparable basis and 12% growth in operating profits, despite the negative impact of the revised pricing for products listed in the National List of Essential Medicines (NLEM). Exports for the quarter grew by 30% as compared to Q2 2022.
The Company was largely able to maintain its gross margins, despite the NLEM impact. The Profit from Operations for the quarter were at INR 168 crores versus INR 150 crores in the previous year, i.e., a growth of 12% while the operating margins increased from 21.5% in Q2 2022 to 23.7% in Q2 2023. The improved operating margins were a result of the Company’s focus mainly on lowering expenses through overall operating efficiencies.
The Company continues to make good progress on its ‘India for India’ strategy through go-to[1]market initiatives, improving operating efficiency and promoting innovation.
Rodolfo Hrosz, Managing Director, Sanofi India Limited “The Company has delivered a strong second quarter performance despite the NLEM impact. The Company’s ‘India for India’ strategy reflects Sanofi’s ambition in the Indian Market. The Company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its established and innovative products in India.”
Sanofi operates in India through two local entities, namely Sanofi India Limited and Sanofi Healthcare India Pvt. Limited.
Read also: Sanofi India People Director Gaurav Bahadur resigns
